today’s cyclodextrin:
is a beautiful review on labeled CD-based imaging probes from University of Debrecen (Zita Képes, István Hajdu, Ferenc Fenyvesi, and György Trencsényi).
As malignancies remain one of the major health concerns worldwide, increasing focus has been centered on the application of cyclodextrins (CDs) in cancer imaging and therapy due to their outstanding inclusion-forming capability. Studies applying fluorescently- CDs, or CD-based MRI contrast agents revealed much about pharmacokinetics and diagnostic applications; however, derivatives labeled with positron emitters seem superior molecular probes in the investigation of the route of CDs in the biological niche. Exploiting the firm signaling interaction between cancer-related cyclooxygenase-2, prostaglandin E2 (PGE2), and RAS oncoprotein, radioconjugated, PGE2-affine CDs project the establishment of novel imaging probes and therapeutic agents. 

See the full article here: Insights into recent preclinical studies on labelled cyclodextrin-based imaging probes: Towards a novel oncological era